Opinion|Videos|July 29, 2024
Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection
Experts discuss leveraging MAICs for decision-making when choosing a CLL BTK inhibitor.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- How do you choose between BTK inhibitors in patients with relapsed/refractory (R/R) CLL?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
New Survey Highlights Quality-of-Life Benefits of Dry Eye Disease Treatment
2
JAK Inhibitors Reshaped Alopecia Areata Care, but Long-Term Data Gaps Remain
3
Team-Based Telehealth Model Matches In-Person Care for Atopic Dermatitis
4
Comprehensive Smoke-Free Laws Linked to Sustained Drop in CVD Mortality
5